ALK and non-small cell lung carcinoma: Oral TKIs, such as anti-EGFR (gefitinib, erlotinib, afatinib, osimertinib) or anti-ALK (crizotinib, ceritinib, alectinib), are the first-line treatment for patients with stage IV EGFR-mutant or ALK-rearranged NSCLC.